BACKGROUND: To study the pharmacokinetic and -dynamic behavior of landiolol in the presence of dobutamine in healthy subjects of European ancestry. METHODS: We conducted a single-center, prospective randomized study in 16 healthy subjects each receiving an infusion of dobutamine sufficient to increase heart rate by 30 bpm followed by a 60 min infusion of 10 μg/kg/min landiolol. RESULTS: Dobutamine-induced increases in heart rate were stable for at least 20 min before a 60 min landiolol- infusion was started. The dobutamine effects were rapidly antagonized by landiolol within 16 min. A further slight decrease in heart rate during 20-60 min of the landiolol infusion occurred as well. Upon termination of landiolol infusion, heart rate and blood pressure recovered rapidly in response to the persisting dobutamine infusion but did not return to the maximum values before landiolol infusion. The pharmacokinetic parameters of landiolol in presence of dobutamine showed a short half-life (3.5 min) and a low distribution volume (0.3 l/kg). No serious adverse events were observed. CONCLUSION: Landiolol can antagonize the dobutamine-induced increases in heart rate and blood pressure in a fast way. A rapid bradycardic effect until steady-state plasma levels is followed by a slow heart rate reduction. The latter can be attributed to an early desensitization to dobutamine. Consequently, after termination of landiolol, the heart rate did not achieve maximum pre-landiolol values. The pharmacokinetics of landiolol during dobutamine infusion are similar when compared to short- and long-term data in Caucasian subjects. Landiolol in the given dose can thus serve as an antagonist of dobutamine-induced cardiac effects. TRIAL REGISTRATION: Registration number 2010-023311-34 at the EU Clinical Trials Register, registration date 2010-12-21.

Aixial s r o Brno Czech Republic

AOP Orphan Pharmaceuticals AG Vienna Austria

Center for Pharmacology and Analysis s r o Plzeň Czech Republic

MRN Medical Research Network GmbH Postgasse 11 22 A 1010 Vienna Austria

Zobrazit více v PubMed

Andrews TC, Reimold SC, Berlin JA, Antman EM. Prevention of supraventricular arrhythmias after coronary artery bypass surgery. A meta-analysis of randomized control trials. Circulation. 1991;84(Suppl):III236–III244. PubMed

Kowey PR, Taylor JE, Rials SJ, Marinchak RA. Meta-analysis of the effectiveness of prophylactic drug therapy in preventing supraventricular arrhythmia early after coronary artery bypass grafting. Am J Cardiol. 1992;69:963–965. doi: 10.1016/0002-9149(92)90802-6. PubMed DOI

Crystal E, Connolly SJ, Sleik K, Ginger TJ, Yusuf S. Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis. Circulation. 2002;106:75–80. doi: 10.1161/01.CIR.0000021113.44111.3E. PubMed DOI

Iguchi S, Iwamura H, Nishizaki M, Hayashi A, Senokuchi K, Kobayashi K, et al. Development of a highly cardioselective ultra short-acting β-blocker, ONO-1101. Chem Pharm Bull(Tokyo) 1992;40:1462–1469. doi: 10.1248/cpb.40.1462. PubMed DOI

Atarashi H, Kuruma A, Ino T, Saitoh H, Onodera T, Ono T, et al. ONO-1101: a new ultra-short acting β-adrenergic blocker: initial study of efficacy, safety and pharmacokinetics. Cardiovasc Drugs Ther. 1993;7(Suppl 2):444.

Taenaka N, Kikawa S. The effectiveness and safety of landiolol hydrochloride, an ultra-short-acting β1-blocker, in postoperative patients with supraventricular tachyarrhythmias: a multicenter, randomized, double-blind, placebo-controlled study. Am J Cardiovasc Drugs. 2013;13:353–364. doi: 10.1007/s40256-013-0035-2. PubMed DOI PMC

Jinzaki M, Hirano M, Hara K, Suzuki T, Yamashina A, Ikari Y, et al. A randomized, double-blind, placebo-controlled, phase II dose-finding study of the short acting β1-blocker, landiolol hydrochloride, in patients with suspected ischemic cardiac disease. Int J Cardiovasc Imaging. 2013;29(Suppl 1):7–20. doi: 10.1007/s10554-013-0253-3. PubMed DOI PMC

Yoshiya I, Ogawa R, Okumura F, Shimada Y, Hanaoka K. Clinical evaluation of landiolol hydrochloride (ONO-1101) on perioperative supraventricular tachyarrhythmia - a phase III, double-blind study in comparison with placebo. Rinsho Iyaku (Jpn J Clin Ther Med) 1997;13:4949(129)–4978(158).

Yoshiya I, Ogawa R, Okumura F, Shimada Y, Hanaoka K. Clinical evaluation of an ultra short acting β1-blocker: landiolol hydrochloride (ONO-1101), on perioperative supraventricular tachyarrhythmia - a double-blind, dose finding study (late phase II study) Rinsho Iyaku (Jpn J Clin Ther Med) 2000;16:1557(113).

Sasao J, Tarver SD, Kindscher JD, Taneyama C, Benson KT, Goto H. In rabbits, landiolol, a new ultra-short-acting β-blocker, exerts a more potent negative chronotropic effect and less effect on blood pressure than esmolol. Can J Anaesth. 2001;48:985–989. doi: 10.1007/BF03016588. PubMed DOI

Iizuka T, Kakinuma T, Hamada Y, Isshiki A. A novel ultra short acting beta-blocker, landiolol supress the central sympathetic nerve activity directory and exerts a more potent negative chronotropic effect and less effect on blood pressure than esmolol. Eur J Anesthesiol. 2004;21(Suppl 32):128. doi: 10.1097/00003643-200406002-00466. DOI

Sugiyama A, Takahara A, Hashimoto K. Electrophysiologic, cardiohemodynamic and beta-blocking actions of a new ultra-short-acting beta-blocker, ONO-1101, assessed by the in vivo canine model in comparison with esmolol. J Cardiovasc Pharmacol. 1999;34:70–77. doi: 10.1097/00005344-199907000-00012. PubMed DOI

Ikeshita K, Nishikawa K, Toriyama S, Yamashita T, Tani Y, Yamada T, et al. Landiolol has a less potent negative inotropic effect than esmolol in isolated rabbit hearts. J Anesth. 2008;22:361–366. doi: 10.1007/s00540-008-0640-4. PubMed DOI

Yamazaki A, Kinoshita H, Shimogai M, Fujii K, Nakahata K, Hironaka Y, et al. Landiolol attenuates tachycardia in response to endotracheal intubation without affecting blood pressure. Can J Anaesth. 2005;52:254–257. doi: 10.1007/BF03016059. PubMed DOI

Xiao J, He P, Zou Q, Zhao Y, Xue Z, Deng X, et al. Landiolol in the treatment of the intraoperative supraventricular tachycardia: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Anesth. 2015;27:120–128. doi: 10.1016/j.jclinane.2014.07.003. PubMed DOI

Murakami M, Furuie H, Matsuguma K, Wanibuchi A, Kikawa S, Irie S. Pharmacokinetics and pharmacodynamics of landiolol hydrochloride, an ultra short-acting β1-selective blocker, in a dose escalation regimen in healthy male volunteers. Drug Metab Pharmacokinet. 2005;20:337–344. doi: 10.2133/dmpk.20.337. PubMed DOI

Saito S, Nishihara F, Akihiro T, Nishikawa K, Obata H, Goto F, et al. Landiolol and esmolol prevent tachycardia without altering cerebral blood flow. Can J Anaesth. 2005;52:1027–1034. doi: 10.1007/BF03021600. PubMed DOI

Sugiura S, Seki S, Hidaka K, Masuoka M, Tsuchida H. The hemodynamic effects of landiolol, an ultra-short-acting β1-selective blocker, on endotracheal intubation in patients with and without hypertension. Anesth Analg. 2007;104:124–129. doi: 10.1213/01.ane.0000249044.40819.e5. PubMed DOI

Hanada K, Higuma T, Nishizaki F, Sukekawa T, Yokota T, Yamada M, et al. Randomized study on the efficacy and safety of landiolol, an ultra-short-acting β1-adrenergic blocker, in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ J. 2012;76:439–445. doi: 10.1253/circj.CJ-11-0947. PubMed DOI

Hasuo H, Tomiyasu S, Hojo M, Fujigaki T, Fukusaki M, Sumikawa K. Effect of ONO-1101, a novel short-acting β-blocker on hemodynamic responses to isoflurane inhalation and tracheal intubation. J Anesth. 1998;12:115–118. doi: 10.1007/BF02480087. PubMed DOI

Higuchi H. Feasibility of continuous intravenous administration of landiolol for acute myocardial infarction: first clinical experience and its safe directions for use. J Am Coll Cardiol. 2010;55(Suppl):A102.E953. doi: 10.1016/S0735-1097(10)60954-0. DOI

Ito S, Konishi T, Imazuru T, Matsuzaki K, Jikuya T. Comparative study between landiolol and amiodarone for therapeutic efficacy after open heart surgery. Kyobu Geka (Jpn J Thorac Surg) 2011;64:1141–1144. PubMed

Ito N, Tashiro T, Morishige N, Nishimi M, Hayashida Y, Minematsu N, et al. Safety and efficacy of an ultrashort-acting β1-blocker on left ventricular dysfunction. Heart Surg Forum. 2012;15:E189–E194. doi: 10.1532/HSF98.20111152. PubMed DOI

Kawaguchi M, Kawaraguchi Y, Yamamoto Y, Hayashi H, Abe R, Inoue S, et al. Effects of landiolol on systemic and cerebral hemodynamics and recovery from anesthesia in patients undergoing craniotomy. J Anesth. 2010;24:503–510. doi: 10.1007/s00540-010-0931-4. PubMed DOI

Kitamura A, Sakamoto A, Inoue T, Ogawa R. Efficacy of an ultrashort-acting β-adrenoceptor blocker (ONO-1101) in attenuating cardiovascular responses to endotracheal intubation. Eur J Clin Pharmacol. 1997;51:467–471. doi: 10.1007/s002280050232. PubMed DOI

Morishima A, Hirao S, Nagasaka S, Yokoyama S, Kaneda K, Nishiwaki N. Suppressive effect of landiolol hydrochloride on atrial fibrillation following surgical repair of acute type a aortic dissection. Jpn J Vasc Surg. 2009;18:481–485.

Nagai R, Kinugawa K, Inoue H, Atarashi H, Seino Y, Yamashita T, et al. Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction: comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin (J-land study) Circ J. 2013;77:908–916. doi: 10.1253/circj.CJ-12-1618. PubMed DOI

Nagaoka E, Arai H, Tamura K, Makita S, Miyagi N. Prevention of atrial fibrillation with ultra-low dose landiolol after off-pump coronary artery bypass grafting. Ann Thorac Cardiovasc Surg. 2014;20:129–134. doi: 10.5761/atcs.oa.12.02003. PubMed DOI

Nakanishi K, Takeda S, Kim C, Kohda S, Sakamoto A. Postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting or cardiac valve surgery: intraoperative use of landiolol. J Cardiothorac Surg. 2013;8:19. doi: 10.1186/1749-8090-8-19. PubMed DOI PMC

Nojiri T, Yamamoto K, Maeda H, Takeuchi Y, Funakoshi Y, Maekura R, et al. Efficacy of low-dose landiolol, an ultrashort-acting β-blocker, on postoperative atrial fibrillation in patients undergoing pulmonary resection for lung cancer. Gen Thorac Cardiovasc Surg. 2011;59:799–805. doi: 10.1007/s11748-011-0841-x. PubMed DOI

Sakamoto A, Kitakaze M, Takamoto S, Namiki A, Kasanuki H, Hosoda S, et al. Landiolol, an ultra-short-acting β1-blocker, more effectively terminates atrial fibrillation than diltiazem after open heart surgery: prospective, multicenter, randomized, open-label study (JL-KNIGHT study) Circ J. 2012;76:1097–1101. doi: 10.1253/circj.CJ-11-1332. PubMed DOI

Sezai A, Minami K, Nakai T, Hata M, Yoshitake I, Wakui S, et al. Landiolol hydrochloride for prevention of atrial fibrillation after coronary artery bypass grafting: new evidence from the PASCAL trial. J Thorac Cardiovasc Surg. 2011;141:1478–1487. doi: 10.1016/j.jtcvs.2010.10.045. PubMed DOI

Sezai A, Nakai T, Hata M, Yoshitake I, Shiono M, Kunimoto S, et al. Feasibility of landiolol and bisoprolol for prevention of atrial fibrillation after coronary artery bypass grafting: a pilot study. J Thorac Cardiovasc Surg. 2012;144:1241–1248. doi: 10.1016/j.jtcvs.2012.06.042. PubMed DOI

Taenaka N, Kikawa S. Dose-dependent effect of landiolol, a new ultra-short-acting β1-blocker, on supraventricular tachyarrhythmias in postoperative patients. Clin Drug Investig. 2013;33:505–514. doi: 10.1007/s40261-013-0093-x. PubMed DOI PMC

Uehara K, Ueyama K, Ito H, Fukuda T, Sasaki K, Abe T, et al. Clinical analysis of precaution against atrial fibrillation following cardiac surgery: Landiolol or amiodarone? Kyobu Geka (Jpn J Thorac Surg) 2010;63:188–191. PubMed

Sakamoto A, Hamasaki T, Kitakaze M. Perioperative landiolol administration reduces atrial fibrillation after cardiac surgery: a meta-analysis of randomized controlled trials. Adv Ther. 2014;31:440–450. doi: 10.1007/s12325-014-0116-x. PubMed DOI PMC

Plosker GL. Landiolol: a review of its use in intraoperative and postoperative tachyarrhythmias. Drugs. 2013;73:959–977. doi: 10.1007/s40265-013-0077-4. PubMed DOI

Krahwinkel W, Ketteler T, Gödke J, Wolfertz J, Ulbricht LJ, Krakau I, et al. Dobutamine stress echocardiography. Eur Heart J. 1997;18(Suppl D):D9–15. doi: 10.1093/eurheartj/18.suppl_D.9. PubMed DOI

Abdullah EE, Pollick C. Symptomatic and hemodynamic recovery following dobutamine stress echo: benefit of low-dose esmolol administration. Int J Card Imaging. 1997;13:53–57. doi: 10.1023/A:1005710309714. PubMed DOI

Weissman NJ, Levangie MW, Guerrero JL, Weyman AE, Picard MH. Effect of beta blockade on dobutamine stress echocardiography. Am Heart J. 1996;131:698–703. doi: 10.1016/S0002-8703(96)90273-2. PubMed DOI

Kijima Y, Yoshima S, Takagi T, Asai M, Lee K, Bando K, et al. Concomitant administration of landiolol and dobutamine in acute heart failure syndrome with atrial tachyarrhythmia. J Card Fail. 2017;23(Suppl):S63. doi: 10.1016/j.cardfail.2017.08.310. DOI

Krumpl G, Ulč I, Trebs M, Kadlecová P, Hodisch J, Maurer G, et al. Pharmacokinetics and pharmacodynamics of low-, intermediate-, and high-dose landiolol and esmolol during long-term infusion in healthy whites. J Cardiovasc Pharmacol. 2018;71:137–146. doi: 10.1097/FJC.0000000000000554. PubMed DOI

Ahonen J, Aranko K, Livanainen A, Maunuksela E-L, Paloheimo M, Olkkola KT. Pharmacokinetic-pharmacodynamic relationship of dobutamine and heart rate, stroke volume and cardiac output in healthy volunteers. Clin Drug Investig. 2008;28:121–127. doi: 10.2165/00044011-200828020-00006. PubMed DOI

Suno M, Kunisawa T, Yamagishi A, Ono T, Yamamoto J, Yamada T, et al. Detection of landiolol using high-performance liquid chromatography/fluorescence: a blood esterase-sensitive ultra-short-acting β1 receptor antagonist. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:1705–1708. doi: 10.1016/j.jchromb.2009.04.017. PubMed DOI

SmPC Dobutamine. https://www.medicines.org.uk/emc/product/6462/smpc. Accessed: 2020 May 06.

Takahata T, Yasui-Furukori N, Sakamoto J, Suto K, Suto T, Tateishi T, et al. Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of landiolol hydrochloride, an ultra-short-acting beta1-blocker. Drugs R D. 2005;6(6):385–394. doi: 10.2165/00126839-200506060-00006. PubMed DOI

Matsumoto N, Aomori T, Kanamoto M, Usui T, Shiga T, Yamamoto K, et al. Influence of hemodynamic variations on the pharmacokinetics of landiolol in patients undergoing cardiovascular surgery. Biol Pharm Bull. 2012;35(10):1655–1660. doi: 10.1248/bpb.b110727. PubMed DOI

Puy Portillo M, del Barrio AS, García-Calonge MA, Martínez JA. Desensitization effect of in vivo treatment with metaproterenol on β1, β2 and β3-responsiveness in rat adipocytes. Life Sci. 1996;58:405–414. doi: 10.1016/0024-3205(95)02305-4. PubMed DOI

Marion-Latard F, de Glisezinski I, Crampes F, Berlan M, Galitzky J, Suljkovicova H, et al. A single bout of exercise induces β-adrenergic desensitization in human adipose tissue. Am J Physiol Regul Integr Comp Physiol. 2001;280:R166–R173. doi: 10.1152/ajpregu.2001.280.1.R166. PubMed DOI

Welsh RC, Warburton DER, Humen DP, Taylor DA, McGavock J, Haykowsky MJ. Prolonged strenuous exercise alters the cardiovascular response to dobutamine stimulation in male athletes. J Physiol. 2005;569:325–330. doi: 10.1113/jphysiol.2005.096412. PubMed DOI PMC

Unverferth DA, Blanford M, Kates RE, Leier CV. Tolerance to dobutamine after a 72-hour continuous infusion. Am J Med. 1980;69(2):262–266. doi: 10.1016/0002-9343(80)90387-3. PubMed DOI

Mateo Martínez A, Martínez Pasqual del Riquelme M, López Ayala JM, Saura Espín D. Coronary vasospasm after dobutamine stress echocardiogram triggered by esmolol. Int J Cardiol. 2015;193:17–19. doi: 10.1016/j.ijcard.2015.04.272. PubMed DOI

Krumpl G, Ulc I, Trebs M, Kadlecová P, Hodisch J. Pharmacokinetics and pharmacodynamics of two different landiolol formulations in a healthy Caucasian group. Eur J Pharm Sci. 2016;92:64–73. doi: 10.1016/j.ejps.2016.06.022. PubMed DOI

Stix G, Wolzt M, Domanovits H, Kadlecová P, Husch B, Trebs M, et al. Open-label two-dose pilot study of landiolol for the treatment of atrial fibrillation/atrial flutter in Caucasian patients. Circ J. 2020;84(1):33–42. doi: 10.1253/circj.CJ-19-0661. PubMed DOI

Dobutamine Alters the Pharmacokinetic and Pharmacodynamic Behavior of Esmolol